Form D · Biotechnology
S2 Genomics, Inc.
Livermore, CA · CIK 0001797955
Offering snapshot reported May 21, 2021 · SEC filing
- Reported sold
- $2.22M Offering amount: $2.5M
- Investors reported
- 17 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 5, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 21, 2021 | Initial | $2,217,365 | No comparison | 17 | SEC filing |
| Dec 24, 2019 | Initial | $2,188,785 | No comparison | 28 | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-400128
Source: Form D, filed May 21, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Michael Finney | Director |
| Shannon Hall | Director |
| Stevan Jovanovich | Director, Executive |
| Roger Mc Intosh | Director |
| Peter Wagner | Director, Executive |
| Michael Wiley | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
6712 Preston Ave, Ste D
Livermore, CA, 94551
Livermore, CA, 94551